NUVB:NYE-Nuvation Bio Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 3.05

Change

0.00 (0.00)%

Market Cap

USD 0.70B

Volume

1.37M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-14 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
NVO Novo Nordisk A/S

-4.90 (-3.58%)

USD 585.29B
BHVN Biohaven Pharmaceutical Holdin..

-0.02 (-0.05%)

USD 3.69B
RCUS Arcus Biosciences Inc

-0.17 (-1.01%)

USD 1.64B
ANRO Alto Neuroscience, Inc.

-0.17 (-1.22%)

USD 0.37B
DNA Ginkgo Bioworks Holdings

+0.58 (+9.31%)

USD 0.35B
ADCT ADC Therapeutics SA

+0.04 (+1.30%)

USD 0.30B
CYBN Cybin Inc

N/A

USD 0.15B
ANVS Annovis Bio Inc

+0.72 (+8.98%)

USD 0.11B
MAIA MAIA Biotechnology Inc.

-0.03 (-1.01%)

USD 0.08B
ARMP Armata Pharmaceuticals Inc

+0.08 (+3.67%)

USD 0.08B

ETFs Containing NUVB

CNCR Loncar Cancer Immunothera.. 1.93 % 0.79 %

-0.20 (-1.26%)

USD 0.01B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 101.99% 94% A 99% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 101.99% 94% A 99% N/A
Trailing 12 Months  
Capital Gain 134.62% 94% A 99% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 134.62% 94% A 99% N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -20.13% 27% F 3% F
Dividend Return -20.13% 27% F 3% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 49.37% 61% D- 18% F
Risk Adjusted Return -40.77% 27% F 8% B-
Market Capitalization 0.70B 89% A- 52% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.